Trial Profile
A study to compare the efficacy drug survival and tolerability of certolizumab-pegol and golimumab in adult patients with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2017
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism